Clinical Trials Browser

Phase 1/2 × INDUSTRY × futuximab × Clear all

NCT02924233 2017-08-28

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung